Form 8-K - Current report:
SEC Accession No. 0001193125-26-220691
Filing Date
2026-05-13
Accepted
2026-05-13 08:32:07
Documents
10
Period of Report
2026-05-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K fate-20260513.htm   iXBRL 8-K 44991
2 EX-99.1 fate-ex99_1.htm EX-99.1 211927
  Complete submission text file 0001193125-26-220691.txt   378405

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT fate-20260513.xsd EX-101.SCH 23928
13 EXTRACTED XBRL INSTANCE DOCUMENT fate-20260513_htm.xml XML 4521
Mailing Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131
Business Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

EIN.: 651311552 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36076 | Film No.: 26971065
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)